– Amgen Inc. said on Monday that US regulators had approved its Aranesp drug–a longer-lasting form of the company’s older anemia drug Epogen–to treat anemia in cancer patients undergoing chemotherapy.
Amgen, based in Thousand Oaks, California, sells Epogen as a treatment for anemia in kidney dialysis patients, but rights to the drug for other indications were licensed early on to Johnson & Johnson, which sells the same drug in the US under the brand name Procrit for patients undergoing chemotherapy.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!